Log In Sign up
The largest database of trusted experimental protocols

Anti psa

Manufactured by Agilent Technologies
Visit Supplier

The Anti-PSA is a laboratory equipment product designed for the detection and measurement of prostate-specific antigen (PSA) in biological samples. It serves as a tool for clinical analysis, providing accurate and reliable PSA quantification.

Automatically generated - may contain errors

Lab products found in correlation

Ne per nuclear and cytoplasmic extraction reagent, by Thermo Fisher Scientific (4 mentions) Ar n 20, by Santa Cruz Biotechnology (2 mentions) Anti oct4, by Merck Group (2 mentions) Anti erk1 2, by Santa Cruz Biotechnology (2 mentions) Anti phospho erk, by Santa Cruz Biotechnology (2 mentions) Anti nanog, by Cell Signaling Technology (2 mentions) Anti parp1 2, by Santa Cruz Biotechnology (2 mentions) Anti α tubulin, by Merck Group (2 mentions) Anti sox2, by Merck Group (2 mentions) Anti p53 do 1, by Santa Cruz Biotechnology (1 mentions) Anti sirt1, by Cell Signaling Technology (1 mentions) Acetyl p53 lys379, by Cell Signaling Technology (1 mentions) Anti erg, by Abcam (1 mentions) Donkey anti rabbit igg hrp, by GE Healthcare (1 mentions) Sheep anti mouse igg hrp, by GE Healthcare (1 mentions) Bicalutamide, by Selleck Chemicals (1 mentions) Enzalutamide, by Selleck Chemicals (1 mentions) Abiraterone, by Selleck Chemicals (1 mentions)

Spelling variants of this product

Anti-PSA antibody (3 citations) Anti-PSA polyclonal antibody (2 citations) Anti-TM (1 citations) Anti-PSA rabbit polyclonal antibody (1 citations)

6 protocols using anti psa

1

Histological and Quantitative Analysis of Prostate Cancer Xenografts

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Intra-femoral tumors were fixed in 10% formalin, decalcified with 10% EDTA, embedded in OCT and frozen in isopentane/dry ice bath for cryosections or paraffin embedded as described in Raheem et al. [14 (link)]. Subcutaneous tumors were fresh frozen in OCT or 10% formalin-fixed and embedded in paraffin at the time of harvest. IF and SC sections were H&E and immunostained with anti-PSA, 1:500 (DAKO) [14 (link)]. Images were captured using the Aperio ScanScope and Keyence digital microscope. Quantitation of PSA staining in FFPE sections was performed using The Spectrum Analysis algorithm package and ImageScope Analysis software as described in Woo et al. [18 (link)] with the modifications that five fields of view were randomly selected in Aperio ScanScope digital images at 20 X magnification in each of three different tumors in each treatment group. Total anti-PSA stained area/total analysis area was calculated for each field of view.
Godebu E., Muldong M., Strasner A., Wu C.N., Park S.C., Woo J.R., Ma W., Liss M.A., Hirata T., Raheem O., Cacalano N.A., Kulidjian A.A, & Jamieson C.A. (2014). PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. Journal of Translational Medicine, 12, 275.
+ Open protocol
+ Expand
2

Prostate Cancer Immunohistochemistry

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemistry was performed on 5-μm sections of radical prostatectomy tissue using anti-AR (Santa Cruz Biotechnology; cat# sc-816, N20 rabbit polyclonal) and anti–prostate specific antigen (anti-PSA; DAKO; cat#A0562, rabbit polyclonal) primary antibodies.
Gillard M., Lack J., Pontier A., Gandla D., Hatcher D., Sowalsky A.G., Rodriguez-Nieves J., Vander Griend D., Paner G, & VanderWeele D. (2017). Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. European urology focus, 5(3), 433-442.
+ Open protocol
+ Expand
3

Protein Expression Analysis in Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were lysed and analysed by SDS-PAGE as previously described [22 (link)]. Antibodies used were: anti-AR 1:500 (AR-N20, Santa Cruz Biotechnology, cat. no sc-816), anti-PSA 1:1000 (DAKO, cat. no A0582), anti-OCT4 1:1000 (Millipore, cat. no MABD76), anti-SOX2 1:1000 (Millipore, cat. no MAB4343), anti-NANOG 1:1000 (Cell Signalling, cat. no 4893), anti-PARP1/2 1:5000 (Santa Cruz Biotechnology, cat. no sc-7150), anti-ERK1/2 1:500 (C-9, Santa Cruz Biotechnology, cat. no sc-514302), anti-phospho-ERK 1:500 (E-4, Santa Cruz Biotechnology, cat. no sc-7383) and anti-α-tubulin 1:4000 (Sigma, cat. no T9026). For cytoplasmic and nuclear fractionation experiments, extracts were separated and prepared using the NE-PER® Nuclear and Cytoplasmic Extraction Reagents according to the manufacturer’s instructions (Thermo Scientific). The chromatin fraction was collected at the end of the extraction.
Hepburn A.C., Steele R.E., Veeratterapillay R., Wilson L., Kounatidou E.E., Barnard A., Berry P., Cassidy J.R., Moad M., El-Sherif A., Gaughan L., Mills I.G., Robson C.N, & Heer R. (2019). The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. Oncogene, 38(22), 4412-4424.
+ Open protocol
+ Expand
4

Protein Expression Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Protein extraction and immunoblot analysis were performed using the standard protocol. Antibodies used were as follows: anti GAPDH (Millipore MAB374), Anti-ERG (Abcam ab92513), Anti-AR (Active Motif 39781), anti-PMEPA1 (ABNOVA H00056937-M01), Anti-PSA (DakoCytomation A05662), anti-p53 DO1 (Santa Cruz biotech, sc126), anti-SIRT1 and Acetyl-p53(Lys379) (Cell Signaling 2493 and 2570).
Kumar P., Sharad S., Petrovics G., Mohamed A., Dobi A., Sreenath T.L., Srivastava S, & Biswas R. (2016). Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. Oncotarget, 7(16), 22791-22806.
+ Open protocol
+ Expand
5

Prostate Cancer Molecular Targets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gamma-Secretase inhibitor I (cat.# 565750) was purchased from Calbiochem/EMD Millipore (Billerica, MA). ERG monoclonal antibody developed by our laboratory (ERG-MAb, 9FY) was obtained from Biocare Medical (Concord, CA). Antibodies against AR (cat.# sc-816), GAPDH (cat.# sc-25778), and α-Tubulin (cat.# sc-5286) were purchased from Santa Cruz (Santa Cruz, CA). Anti-PSA (cat.#A056201-2) antibody was obtained from DAKO cytomation (Carpinteria, CA). Antibodies against NOTCH1 (cat.#3268), NOTCH2 (cat.#4530), EMT antibody sampler kit(cat.# 9782) and apoptosis antibody sampler kit (cat.# 9915) were purchased from Cell Signaling Technologies (Danvers, MA). Sheep anti-mouse IgG-HRP (cat #NXA931) and donkey-anti rabbit IgG-HRP (cat #NA934) were from GE Healthcare (Fairfield, CT). Bicalutamide (cat #S1190), Enzalutamide (cat # S1250) and Abiraterone (cat # S1123) were purchased from Selleckchem (Houston, TX).
Mohamed A.A., Tan S.H., Xavier C.P., Katta S., Huang W., Ravindranath L., Jamal M., Li H., Srivastava M., Srivatsan E., Sreenath T., McLeod D.G., Srinivasan A., Petrovics G., Dobi A, & Srivastava S. (2017). Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-positive Prostate Cancer Cells. Molecular cancer research : MCR, 15(10), 1308-1317.
+ Open protocol
+ Expand
6

Western Blot Analysis of Stem Cell Markers

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were lysed and analysed by SDS-PAGE as previously described [56 (link)]. Antibodies used were: anti-AR 1:500 (AR-N20, Santa Cruz Biotechnology, cat. no sc-816), anti-PSA 1:1000 (DAKO, cat. no A0582), anti-OCT4 1:1000 (Millipore, cat. no MABD76), anti-SOX2 1:1000 (Millipore, cat. no MAB4343), anti-NANOG 1:1000 (Cell Signaling, cat. no 4893), anti-PARP1/2 1:5000 (Santa Cruz Biotechnology, cat. no sc-7150), anti-ERK1/2 1:500 (C-9, Santa Cruz Biotechnology, cat. no sc-514302), anti-phospho-ERK 1:500 (E-4, Santa Cruz Biotechnology, cat. no sc-7383) and anti-α-tubulin 1:4000 (Sigma, cat. no T9026). For cytoplasmic and nuclear fractionation experiments, extracts were separated and prepared using the NE-PER® Nuclear and Cytoplasmic Extraction Reagents according to the manufacturer’s instructions (Thermo Scientific). The chromatin fraction was collected at the end of the extraction.
Hepburn A.C., Steele R.E., Veeratterapillay R., Wilson L., Kounatidou E.E., Barnard A., Berry P., Cassidy J.R., Moad M., El-Sherif A., Gaughan L., Mills I.G., Robson C.N, & Heer R. (2019). The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. Oncogene, 38(22), 4412-4424.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!